(Eds: With fresh inputs) Bhubaneswar, Oct 6 (PTI) At least 2,673 more people tested positive for COVID-19 in Odisha on Tuesday, taking the tally to 2,38,003, while 16 fresh fatalities pushed the death toll to 940, a health department official said.
Of the new cases, 1,554 were reported from various quarantine centres and 1,119 were detected during contact tracing, he said.
Khurda district, of which state capital Bhubaneswar is a part, registered the maximum number of new cases at 448, followed by Cuttack at 214 and Nuapada at 159.
'Regret to inform the demise of sixteen #COVID-19 positive patients while under treatment in hospitals,' the Health and Family Welfare Department said on Twitter.
Of the 16 fatalities, four were reported from Balasore, three from Khurda, two from Cuttack and one each from Angul, Boudh, Mayurbhanj, Nawrangpur, Nayagarh, Puri and Subarnapur districts.
Ganjam district alone reported 221 of the 940 deaths in the state, followed by Khurda at 154 and Cuttack at 82.
The case fatality ratio (CFR) also remains at 0.39 per cent, the official said.
At least 3,817 patients were cured of the disease during the day, taking the total number of recoveries to 2,10,217, which is 88.32 per cent of the state's caseload, the official said.
The state government on Tuesday issued safety guidelines for the people who have been cured of COVID-19.
'Recovered people must wear masks and maintain social distancing norms. They should take a balanced diet with rich protein and less carbohydrate,' health department's technical advisor Prof Jayanta Panda said.
Odisha currently has 26,793 active cases, which accounted for 11.25 per cent of the state's caseload.
Fifty-three coronavirus patients have died due to comorbidities, according to the official.
As many as 35.24 lakh tests for COVID-19 have been conducted so far, including 41,840 on Monday.
Meanwhile, the Odisha government has allowed the use of Favipiravir tablets by coronavirus patients during home isolation.
Nearly 80 per cent of COVID-19 patients are under home isolation in the state, Panda said.
'New clinical inputs and empirical evidence about the pandemic have proved the effectiveness of Favipiravir tablet as an anti-viral medicine to treat coronavirus patients, Chief Secretary A K Tripathy said after consulting with doctors and health experts.
He also said the medicine needs to be administered with proper advice and precaution.
The chief secretary directed the health department to circulate the standard operating procedure for the use of Favipiravir tablets among doctors.
The rapid response teams (RRTs) of the state government will be trained to assess the condition of the patients in home isolation and whether they can be administered Favipiravir tablets at their residences in consultation with trained doctors. PTI AAM BDC BDC